Resources Repository
-
ArticlePublication 2008Cost-Effectiveness of Rapid Point-of-Care Prenatal Syphilis Screening in Sub-Saharan Africa
This paper investigates the cost-effectiveness of using rapid point-of-care tests for prenatal syphilis screening among …
This paper investigates the cost-effectiveness of using rapid point-of-care tests for prenatal syphilis screening among pregnant women in sub-Saharan Africa, a region with syphilis prevalence rates as high as 17%, and where traditional multi-test screening methods have been challenging to implement. Focusing on newly available rapid point-of-care screening tests, strategies differed by the initial test [rapid plasma reagin (RPR), immunochromographic strip (ICS)], need for confirmation with Treponema pallidum hemagglutination assay, and number of visits required.…
Technology Assessment | Cost-Effectiveness Analysis | Costing Methods | Test Performance | Mathematical Models | Infectious Diseases | Maternal/Reproductive Health | Clinical Care | Health/Medicine | Sub-Saharan Africa -
GuidelinesPublication 2016Second Panel on Cost-Effectiveness in Health and Medicine
This article provides an overview of the main recommendations of the 2016 Second Panel on …
This article provides an overview of the main recommendations of the 2016 Second Panel on Cost-Effectiveness in Health and Medicine. In 1993, the U.S. Public Health Service convened the first panel of experts to review the state of cost-effectiveness analysis and to develop guidelines for its use in health, to improve quality and promote comparability. Scientists and scholars in economics, clinical medicine, ethics, and statistics met to share expertise and develop recommendations by consensus. The…
Technology Assessment | Cost-Effectiveness Analysis | Priority Setting/Ethics | Costing Methods | Evidence Synthesis | Health/Medicine | North America -
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Technology Assessment | Cost-Effectiveness Analysis | Preferences/Values | Health Outcomes | Mathematical Models | Health Systems | Health/Medicine | Science/Technology | North America | Europe -
ArticlePublication 2016An Economic Evaluation of the PEN Program in Indonesia
Responding to the economic and health burden of noncommunicable diseases (NCDs), the World Health Organization (WHO) …
Responding to the economic and health burden of noncommunicable diseases (NCDs), the World Health Organization (WHO) introduced the Package of Essential Noncommunicable disease (PEN) interventions. Several countries, including Indonesia, implemented the PEN program. To assess the value of the investment in the current program, an economic evaluation of the program was conducted with collaboration between the Ministry of Health in Indonesia, the WHO, and the International Decision Support Initiative (iDSI). This study evaluated the delivery of…
Technology Assessment | Cost-Effectiveness Analysis | Priority Setting/Ethics | Chronic Disease/Risk | Health Systems | Economics/Finance | Government/Law | Health/Medicine | Asia & Pacific -
GuidelinesPublication 2013Guide to the Methods of Technology Appraisal 2013
The National Institute for Health and Care Excellence (NICE, or the Institute) provides guidance to …
The National Institute for Health and Care Excellence (NICE, or the Institute) provides guidance to the NHS in England on the clinical and cost effectiveness of selected new and established technologies. The Institute undertakes appraisals of health technologies at the request of the Department of Health. Guidance produced by the Institute on health technologies is also applied selectively in Northern Ireland, Scotland and Wales. The purpose of this document is to provide an overview of…
Technology Assessment | Cost-Effectiveness Analysis | Priority Setting/Ethics | Health Systems | Policy/Regulation | Government/Law | Health/Medicine | Europe -
ArticlePublication 2024Hypertension Care Cascades and Reducing Inequities in Cardiovascular Disease in LMIC
This study investigates the distributional implications of enhancing hypertension control in low- and middle-income countries …
This study investigates the distributional implications of enhancing hypertension control in low- and middle-income countries (LMICs) across wealth quintiles. Using individual-level data from nationally representative surveys in 44 LMICs, the researchers simulated improvements in the hypertension care cascade and assessed the distributional benefits. They raised diagnosis and treatment levels for all wealth quintiles to match the best-performing country quintile and estimated the resulting change in 10-year cardiovascular disease (CVD) risk. Results indicate greater health benefits…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine -
ArticlePublication 2024Extended Cost-Effectiveness Analysis of Interventions to Improve Uptake of Diabetes Services in South Africa
This study examines the potential impact of a conditional cash transfer (CCT) program on diabetes …
This study examines the potential impact of a conditional cash transfer (CCT) program on diabetes diagnosis and treatment service utilization in South Africa (SA) using extended cost-effectiveness analysis (ECEA). Applying a Markov model over a 45-year period, the analysis compares costs, health benefits, and financial risk protection (FRP) attributes of different CCT strategies, drawing from SA-specific data. Three scenarios were simulated: covering diagnosis services only, treatment services only, and both diagnosis and treatment services. Cost-effectiveness,…
Cost-Effectiveness Analysis | Health Outcomes | Mathematical Models | Chronic Disease/Risk | Policy/Regulation | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2023Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control …
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control in the US. A cost-effectiveness analysis was conducted using a Markov model based on the pharmacist-prescribing intervention used in The Alberta Clinical Trial in Optimizing Hypertension (or RxACTION). Outcomes included cardiovascular (CV) events, end-stage kidney disease events, life years, quality-adjusted life years (QALYs), lifetime costs, and lifetime incremental cost-effectiveness ratio (ICER). Costs were based on reimbursement rates, published literature, national…
Cost-Effectiveness Analysis | Mathematical Models | State-Transition | Chronic Disease/Risk | Clinical Care | Health/Medicine | North America -
ArticlePublication 2023Cost-Effectiveness of Intensive vs. Standard Blood Pressure Control Among Older Patients
This economic analysis explored the cost-effectiveness of intensive vs standard blood pressure control in older …
This economic analysis explored the cost-effectiveness of intensive vs standard blood pressure control in older hypertensive patients between 60 and 80 years in China, the US, and the UK. Treatment outcome data from the Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension (STEP trial) and different cardiovascular risk assessment models for a hypothetical cohort of STEP-eligible patients were used. Costs and utilities were obtained from published sources. A Markov model was used to…
Cost-Effectiveness Analysis | Mathematical Models | Chronic Disease/Risk | Clinical Care | North America